Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

27.98 +0.09 (+0.34%)
Streaming Delayed Price Updated: 1:47 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 916,408
Open 27.85
Bid (Size) 27.98 (5)
Ask (Size) 27.99 (4)
Prev. Close 27.89
Today's Range 27.69 - 28.09
52wk Range 25.92 - 36.48
Shares Outstanding 388,132,400
Dividend Yield 2.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire

Performance

YTD
-1.01%
-1.01%
1 Month
-7.27%
-7.27%
3 Month
-0.20%
-0.20%
6 Month
-0.44%
-0.44%
1 Year
-22.78%
-22.78%

More News

Read More
3 Pharma Stocks to Sell in April Before They Crash & Burn
Via InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
Via InvestorPlace
Looking Into Royalty Pharma's Recent Short Interest
Via Benzinga
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
Via Chartmill
Earnings Scheduled For February 15, 2024
Via Benzinga
Royalty Pharma's Earnings: A Preview
Via Benzinga
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
Via InvestorPlace
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
Via InvestorPlace
For those who appreciate value investing, NASDAQ:RPRX is a compelling option with its solid fundamentals.
Via Chartmill
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
Via The Motley Fool
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
Via Chartmill
Royalty Pharma Reports Q4 and Full Year 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
How Risky Is Royalty Pharma’s Dividend?
Via Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
From Royalty Pharma plc
Via GlobeNewswire
Top Stocks That Just Increased Their Dividends
Via Talk Markets
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.